Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus (NCT05306873), a randomized phase 2 study. The primary outcome is The Percentage of Participants Who Experience a Stage 2 Treatment Failure at or Before the Stage 2 Week 24 Visit..

2. Clinical Question

The study also aimed to explore gene-expression patterns among responders and non-responders and immunologic changes accompanying improvement or loss of clinical response. These are exploratory aims described in the registry; the record does not report analyses addressing them.

3. Trial Design

The registry describes a Phase 2, randomized, triple-masked, parallel-group study sponsored by the National Institute of Allergy and Infectious Diseases. The condition listed is systemic lupus erythematosus. Enrollment was 12, and the study status is terminated. The recorded study start was 2022-11-30, and primary completion was 2024-06-13. The reason for termination is not reported in the registry record.

The study had multiple stages. The primary outcome concerns Stage 2, where the listed arms were MMF and placebo for MMF. The primary outcome population included Stage 2 randomized participants who received at least one dose of Stage 2 study drug. The registry reports 4 participants in each of these arms for the primary outcome. The title and study description also identify a comparison involving MMF with voclosporin, and the adverse-event record lists Stage 3 groups. The record does not give enough detail to reconstruct the full participant flow across stages or explain how each stage’s allocation was conducted.

The listed interventions include MMF, placebo for MMF, voclosporin, and placebo for voclosporin. The MMF arm description starts with a dose escalation and then describes a stable dose, but portions of the arm descriptions are incomplete in the registry record. The description for the MMF-plus-voclosporin and MMF-plus-placebo groups says treatment could continue for up to 24 weeks and notes that a single intramuscular injection of a long-acting corticosteroid could be given during the first 2 weeks if needed. The available text does not establish all treatment details or the full sequence of stages.

Randomization can help balance measured and unmeasured characteristics between groups on average, while masking is intended to limit the influence of knowledge of treatment assignment. These are general design principles, not evidence that balance was achieved in this small trial. The registry does not report the randomization procedure, the identities of the masked parties, or the sample-size justification.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: A total of 12 participants consented from November 2022 to April 2024 at 7 sites.

Stage 2

Reasons for not completing this period:

Stage 3

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The modified Intent-to-Treat population includes all Stage 2 randomized participants who received at least one dose of Stage 2 study drug.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The modified Intent-to-Treat population includes all Stage 2 randomized participants who received at least one dose of Stage 2 study drug.

6. Primary Endpoint

The registry lists the primary outcome as The Percentage of Participants Who Experience a Stage 2 Treatment Failure at or Before the Stage 2 Week 24 Visit., measured over From Baseline to Stage 2 Week 24.

The primary endpoint is the number of participants who experienced Stage 2 treatment failure at or before the Stage 2 Week 24 visit, from baseline through that visit. The registry labels the endpoint as a percentage, but the posted arm results are counts: 2 participants among 4 in the Stage 2 MMF arm and 2 among 4 in the Stage 2 placebo-for-MMF arm. No uncertainty interval or inferential result is posted for this comparison.

Treatment failure is a composite outcome. It includes the first qualifying event after Stage 2 randomization: use of methylprednisolone acetate injection or initiation or increase of a lupus medication, with an exception for occasional corticosteroid use unrelated to an SLE flare; a qualifying BILAG flare accompanied by investigator-assessed worsening on the Clinician Global Impression of Change; or premature permanent discontinuation of assigned treatment for any reason. The BILAG component refers to new or worse findings that could support a severe flare in one item or a moderate flare across two organs, together with the specified worsening assessment.

A composite endpoint can capture several ways a participant may fail to remain on the assigned treatment strategy, rather than focusing on one clinical event. It can therefore be useful for a trial question that includes rescue treatment, worsening, and treatment discontinuation. As a general limitation, different components may have different clinical meanings and may contribute differently to the overall count. The registry does not provide component-specific Stage 2 counts, so the posted results do not show which type of event accounted for treatment failures.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What kind of outcome is being counted?

The primary endpoint is binary at the participant level: each participant either met the composite treatment-failure definition during the specified period or did not. The registry reports the number of participants with the event in each arm, alongside the number included in that arm. For Stage 2 MMF, the record reports 2 events among 4 participants; for Stage 2 placebo for MMF, it also reports 2 among 4. These are the posted counts, not an adjusted treatment-effect estimate.

For a binary outcome, an analysis might compare event proportions, estimate a difference or ratio between groups, or fit a regression model. These are general analytical options, not methods reported for this trial. The registry record does not report which inferential method, if any, was planned or used for the primary comparison. No confidence interval or p-value is posted.

Why does the composite definition matter?

The endpoint combines treatment rescue or medication changes, a qualifying flare with associated worsening, and permanent treatment discontinuation. Combining events can make an endpoint reflect several clinically relevant forms of failure. However, the composite count does not reveal the contribution of each component. A participant counted because of medication escalation may differ in event experience from a participant counted because of a qualifying flare or discontinuation. Component-specific results are not reported in the registry record.

The definition also specifies what qualifies for the BILAG flare component and requires an accompanying worsening assessment. This operational detail matters because endpoint rules determine which observations are counted as events. The posted total cannot be interpreted without that definition, and the same total could arise from different mixtures of components. The registry does not report adjudication procedures or additional details about how endpoint events were reviewed.

What does randomization contribute?

Random assignment is intended to make treatment groups comparable in expectation, reducing systematic differences in prognosis that could otherwise bias a comparison. Masking can reduce the possibility that knowledge of assignment influences care, outcome assessment, or reporting. These are general principles. They do not guarantee that small groups will be balanced on relevant characteristics, and the registry does not report baseline characteristics for the Stage 2 groups in the registry record for this analysis.

The study is recorded as randomized, triple-masked, and parallel-group. The record does not specify the randomization sequence, concealment procedure, identities of the masked parties, or whether masking was maintained. The design labels alone do not establish how these procedures were implemented.

How should uncertainty be understood?

Observed counts are subject to sampling variability: different participants, even under the same underlying treatment effect, could produce different counts. General statistical inference uses an estimate and its uncertainty to show how much the data constrain plausible effects. A confidence interval is one way to display that uncertainty. With small sample sizes, binary-outcome estimates may be especially imprecise, and standard large-sample approximations can be unreliable. The registry record does not report an interval or method for this endpoint, so there is no basis for stating a numerical range of plausible effects.

Over-dispersion is a general concern when observed variability exceeds what a chosen statistical model assumes. It is more directly relevant to certain count or repeated-measure models than to a simple participant-level binary endpoint. If a model assumes less variability than is present, its uncertainty estimates can be too narrow. No such model or over-dispersion assessment is reported for this trial, and the posted binary counts do not permit one to assess it.

What do the planning illustrations represent?

The registry entries describe planning illustrations based on the observed effect, with a two-sided significance level of 0.05, equal allocation between arms, and a normal approximation. The target effect is described as a stated fraction of the observed effect. These are planning calculations, not the trial’s original sample-size justification. The record does not report the trial’s own sample-size rationale or its assumed effect.

Sample-size calculations estimate how many participants may be needed under specified assumptions to detect a target effect with a chosen power. They are planning tools, not evidence about the probability that the completed study’s result is correct. In particular, a sample-size illustration is not observed power. If a calculation is based on an effect observed in a small study, that effect can be unstable; planning around it does not remove uncertainty about the effect itself. The registry’s note that values are missing or not estimable for a two-arm binary comparison means no usable two-arm planning value is available in that record.

For time-to-event outcomes, the planning note describes total events; for other outcomes, it describes participants per arm. Those general conventions do not change the fact that the posted primary outcome is a binary participant-level count. The registry record does not report a trial-specific power target, anticipated loss to follow-up, or a formal sample-size calculation for the original design.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Stage 2 MMF", "Stage 2 Placebo for MMF")
n      <- c(4, 4)
events <- c(2, 2)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Stage 2 MMF  4  2  50.0  6.8  93.2  15.0  85.0  14.7  85.3
ARM  Stage 2 Placebo for MMF  4  2  50.0  6.8  93.2  15.0  85.0  14.7  85.3

11. Multiplicity, Missing Data and Analysis Populations

The registry lists 16 outcome measures and 15 posted secondary outcomes, while the primary outcome is the Stage 2 treatment-failure count. Secondary outcomes include Stage 2 and Stage 3 clinical response using BICLA, Stage 3 treatment failure and time to treatment failure, and specified adverse-event and infection outcomes. Considering several outcomes can raise a multiplicity issue: when many hypotheses are tested, the chance of at least one apparently notable result can increase. General approaches include prespecifying a primary outcome, adjusting for multiple comparisons, or treating secondary analyses as exploratory.

The registry record does not report a multiplicity strategy, a hierarchy among secondary outcomes, or whether any adjustment was planned or performed. It also lists 0 analyses. The record therefore does not support conclusions about which outcomes were formally tested or how any tests were interpreted. The absence of a posted analysis is not evidence that no analysis was performed outside the registry.

Missing-data methods are not reported in the registry record. The primary population is defined as Stage 2 randomized participants who received at least one dose of Stage 2 study drug, but the record does not describe how missing Week 24 outcome information was handled, whether participants with incomplete follow-up were counted as failures, or whether sensitivity analyses were conducted. The arm counts do not provide enough information to infer the completeness of outcome ascertainment.

The modified Intent-to-Treat definition also differs from an analysis including every randomized participant, because it requires receipt of at least one dose. The record does not report a separate all-randomized analysis population or other analysis populations. The Stage 2 primary-outcome results should therefore be understood using the registry’s stated population definition, without assuming how participants outside that definition were handled.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: nephrolithiasis (25.0%).

The registry separates serious adverse events from other adverse events and reports the number of participants at risk and the number affected in each stage group. In Stage 1, 0 of 12 participants had a serious adverse event and 2 of 12 had another adverse event. In Stage 2 MMF, the corresponding counts were 0 of 4 and 3 of 4. In Stage 2 placebo, they were 1 of 4 and 3 of 4. In Stage 3 MMF plus voclosporin, they were 0 of 2 and 1 of 2; in Stage 3 MMF plus placebo, they were 0 of 1 and 0 of 1. The registry reports 0 deaths in each group.

These counts describe participants with events; they are not event rates adjusted for time at risk, and the record does not provide such an adjustment. The groups also differ in size, particularly across stages, so raw counts should not be treated as direct comparisons of risk. A participant may experience more than one event, and the counts of participants affected do not necessarily equal the total number of event episodes.

Nephrolithiasis is listed among the top serious-event terms with 25.0%. The registry summary does not provide enough context in this record to explain the denominator or other details of that term. These safety summaries are descriptive and do not establish that a treatment caused or prevented an event.

13. What the Result Does, and Does Not, Mean

The posted primary-outcome results show the same number of Stage 2 treatment failures in the MMF and placebo-for-MMF groups: 2 participants in each group, with 4 participants reported per arm. This is the main direct numerical comparison available for the primary endpoint. It does not show how precisely the underlying treatment effects are estimated, because the registry does not provide a confidence interval or inferential analysis.

Equal observed counts do not establish equivalence, non-inferiority, or absence of a treatment effect. Those conclusions require a prespecified framework and an analysis that accounts for uncertainty. No equivalence or non-inferiority margin is reported, and no statistical analysis result is posted. A small trial can produce matching counts even when the underlying event probabilities differ; that is a general consequence of sampling variability, not a claim about the true effect in this study.

The endpoint is also a composite. The posted totals do not identify whether failures arose from rescue medication, a qualifying flare with worsening, or treatment discontinuation. Nor are the primary counts divided by immunologically defined subsets, even though the study’s stated aim was to assess treatment effects in those subsets. The registry describes gene-expression and immunophenotyping objectives, but does not report results for them.

The safety summaries show recorded serious and other adverse events across the listed stages, including one serious adverse event in the Stage 2 placebo group and none in the Stage 2 MMF group. Small numbers and differing group sizes limit interpretation, and the registry record does not establish causal attribution from these counts. The reason the trial was terminated is not reported in the registry record.

Accordingly, the record supports a narrow descriptive statement about the Stage 2 counts and the listed safety observations. It does not support a definitive claim about efficacy, lack of efficacy, equivalence, subgroup effects, or comparative safety. The missing inferential results, limited Stage 2 group sizes, and incomplete reporting of analysis and missing-data procedures are important when judging what can be concluded.

14. Why This Trial Matters Statistically

This trial is statistically notable because its primary question is embedded in a staged study that aims to connect treatment response with immunologically defined subsets. That creates a distinction between an overall treatment comparison and a question about whether treatment effects vary across biological subgroups. The registry describes both aims, but the posted primary outcome is an overall Stage 2 count, with no subgroup-specific estimates reported.

For researchers, the record illustrates why an outcome definition and an analysis population need to be read together. Treatment failure includes several types of events, and the modified Intent-to-Treat population includes only Stage 2 randomized participants who received at least one dose. Those details determine what the primary count represents. Without component-specific results, complete participant flow, or information on missing outcomes, the scope of the summary is limited.

The reported Stage 2 counts are small and match across the two arms. In general, small groups provide limited information about the range of effects compatible with the data. Reporting an effect estimate with an uncertainty interval, a prespecified analysis method, and transparent handling of incomplete follow-up would help readers assess precision. Those inferential details are not reported in the registry record.

The trial also highlights the difference between an original design calculation and planning illustrations based on observed results. The registry note characterizes the calculations as planning illustrations, not the study’s own design justification. Such illustrations should not be mistaken for observed power or for evidence that a study was adequately sized. The original sample-size justification is not reported.

Finally, termination status is relevant context, but without a stated reason it should not be used to infer why the study ended or what happened to the planned analyses. Careful interpretation separates the registry entries, descriptive counts, and general statistical principles rather than treating them as interchangeable.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific gaps constrain interpretation. The registry reports enrollment of 12 overall and 4 participants per Stage 2 arm for the primary outcome, but the full participant flow through the study stages is not reported in the registry record. It is therefore not possible to reconstruct how participants entered or left each stage from the posted summary.

The trial is marked terminated, but the reason for termination is not reported in the registry record. The available record also does not explain whether termination affected follow-up, completion of planned assessments, or the timing and scope of analyses. No explanation should be inferred from the status alone.

The primary outcome counts are not accompanied by an inferential comparison, confidence interval, or component-specific breakdown. The registry’s outcome description includes several possible forms of treatment failure, but the posted results do not show their separate contributions. This limits both assessment of precision and understanding of what drove the total count.

The trial’s stated focus on immunologically defined subsets is not matched by posted subset-specific primary results in this record. The description also identifies gene-expression and immunophenotyping aims, but no analyses for those aims are reported. The number of participants available for any such analysis is not reported in the registry record.

Details needed to assess the analysis are also absent: the randomization procedure, the sample-size justification, a statistical analysis plan, multiplicity handling, and missing-data methods are not reported in the registry record. Baseline characteristics for the Stage 2 groups and a complete account of endpoint ascertainment are not included in the registry record. These omissions mean that the counts are best treated as a limited descriptive result rather than a complete account of the trial’s evidence.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus — NCT05306873.
• Registry record last updated 2025-09-09; status last verified 2025-09.
• Results first posted 2025-09-09.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

This registry record describes a Phase 2, randomized, triple-masked, parallel-group study of treatment strategies for systemic lupus erythematosus. Overall enrollment was 12. The study status is terminated; the recorded start date is 2022-11-30 and primary completion date is 2024-06-13. The reason for termination is not reported in the registry record.

The primary outcome is Stage 2 treatment failure by the Stage 2 Week 24 visit. The record reports 2 participants with treatment failure among 4 in the Stage 2 MMF arm and 2 among 4 in the Stage 2 placebo-for-MMF arm. No inferential analysis or uncertainty interval is posted. Safety summaries list serious and other adverse events across the study stages, with 0 deaths reported in each group.

The study description emphasizes evaluation within immunologically defined subsets and exploration of gene-expression and immunologic changes. Subset analyses, analysis methods, missing-data procedures, multiplicity plans, and the original sample-size justification are not reported in the registry record. The posted results therefore support description of the recorded counts, but not a precise or definitive treatment-effect conclusion.